The Rel/NF-κB family: Friend and foe

Trends in Biochemical Sciences

Volumn 25, Issue 9, 2000, Pages 434-440

  Perkins, Neil D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; DORSAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; ONCOPROTEIN; ONCOPROTEIN C REL; ONCOPROTEIN V REL; PROTEIN P100; PROTEIN P50; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

APOPTOSIS; CANCER; CELL ACTIVATION; CELL TYPE; DRUG DESIGN; DRUG TARGETING; GENE EXPRESSION; GENETIC ANALYSIS; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SEQUENCE HOMOLOGY; STRESS;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE; CELL NUCLEUS; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; MODELS, BIOLOGICAL; MULTIGENE FAMILY; NEOPLASMS; NF-KAPPA B; TRANSCRIPTION, GENETIC;

EID: 0034283837     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0004(00)01617-0     Document Type: Review

References (50)

1. Sen R.et al. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 46:1986;705-716.
2. Baldwin A.S. THE NF-κB and IκB proteins. new discoveries and insights Annu. Rev. Immunol. 14:1996;649-681.
3. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 18:1999;6853-6866.
4. Karin M. How NF-κB is activated. the role of the IκB kinase (IKK) complex Oncogene. 18:1999;6867-6874.
5. Gerondakis S.et al. Genetic approaches in mice to understand Rel/NF-κB and IκB function. transgenics and knockouts Oncogene. 18:1999;6888-6895.
6. Rudolph D.et al. Severe liver degeneration and lack of NF-κB activation in NEMO/IKK gamma-deficient mice. Genes Dev. 14:2000;854-862.
7. Bushdid P.B.et al. Inhibition of NF-κB activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis. Nature. 392:1998;615-618.
8. Kanegae Y.et al. Role of Rel/NF-κB transcription factors during the outgrowth of the vertebrate limb. Nature. 392:1998;611-614.
9. Peters R.T.et al. IKKε is part of a novel PMA-inducible IκB kinase complex. Mol. Cell. 5:2000;513-522.
10. Sanz L.et al. The interaction of p62 with RIP links the atypical PKCs to NF-κB activation. EMBO J. 18:1999;3044-3053.
11. Romashkova J.A.et al. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 401:1999;86-90.
12. Ozes O.N.et al. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 401:1999;82-85.
13. Tojima Y.et al. NAK is an IκB kinase-activating kinase. Nature. 404:2000;778-782.
14. Kane L.P.et al. Induction of NF-κB by the Akt PKB kinase. Curr. Biol. 9:1999;601-604.
15. Sizemore N.et al. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-κB p65/RelA subunit. Mol. Cell. Biol. 19:1999;4798-4805.
16. Madrid L.V.et al. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB. Mol. Cell. Biol. 20:2000;1626-1638.
17. Perkins N.D. Achieving transcriptional specificity with NF-κB. Int. J. Biochem. Cell Biol. 29:1997;1433-1448.
18. Zhong H.H.et al. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell. 1:1998;661-671.
19. Shikama N.et al. The p300/CBP family. integrating signals with transcription factors and chromatin Trends Cell Biol. 7:1997;230-236.
20. Hottiger M.O.et al. Modulation of cytokine-induced HIV gene expression by competitive binding of transcription factors to the coactivator p300. EMBO J. 17:1998;3124-3134.
21. Kaltschmidt B.et al. Transcription factor NF-κB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2642-2647.
22. Barnes P.J.et al. Mechanisms of disease- nuclear factor-κB- a pivotal transcription factor in chronic inflammatory diseases. New Engl. J. Med. 336:1997;1066-1071.
23. Johnson C.et al. An N-terminal nuclear export signal is required for the nucleocytoplasmic shuttling of IκB alpha. EMBO J. 18:1999;6682-6693.
24. Song H.Y.et al. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc. Natl. Acad. Sci. U. S. A. 93:1996;6721-6725.
25. Schottelius A.J.G.et al. Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding. J. Biol. Chem. 274:1999;31868-31874.
26. Rossi A.et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature. 403:2000;103-108.
27. Barkett M.et al. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene. 18:1999;6910-6924.
28. Rayet B.et al. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 18:1999;6938-6947.
29. Foo S.Y.et al. NF-κB to the rescue - RELs, apoptosis and cellular transformation. Trends Genet. 15:1999;229-235.
30. Hanahan D.et al. The hallmarks of cancer. Cell. 100:2000;57-70.
31. Kasibhatla S.et al. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol. Cell. 1:1998;543-551.
32. Levkau B.et al. Apoptosis overrides survival signals through a caspase-mediated dominant negative NF-κB loop. Nat. Cell Biol. 1:1999;227-233.
33. Ryan K.M.et al. Role of NF-κB in p53-mediated programmed cell death. Nature. 404:2000;892-897.
34. Kawai H.et al. Down-regulation of nuclear factor κB is required for p53-dependent apoptosis in X-ray-irradiated mouse lymphoma cells and thymocytes. Cancer Res. 59:1999;6038-6041.
35. Pise-Masison C.A.et al. Inactivation of p53 by human T-cell lymphotropic virus type 1 tax requires activation of the NF-κB pathway and is dependent on p53 phosphorylation. Mol. Cell. Biol. 20:2000;3377-3386.
36. Hellin A.C.et al. Nuclear factor-κB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene. 16:1998;1187-1195.
37. Webster G.A.et al. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19:1999;3485-3495.
38. Guttridge D.C.et al. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19:1999;5785-5799.
39. Cabannes E.et al. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα Oncogene. 18:1999;3063-3070.
40. Krappmann D.et al. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 18:1999;943-953.
41. Nakshatri H.et al. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 17:1997;3629-3639.
42. Reuther J.Y.et al. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev. 12:1998;968-981.
43. Jo H.et al. NF-κB is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene. 19:2000;841-849.
44. Dechend R.et al. The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators. Oncogene. 18:1999;3316-3323.
45. Wang C.Y.et al. Control of inducible chemoresistance. enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB Nat. Med. 5:1999;412-417.
46. Epinat J.C.et al. Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene. 18:1999;6896-6909.
47. Bondeson J.et al. Defining therapeutic targets by using adenovirus. blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators Proc. Natl. Acad. Sci. U. S. A. 96:1999;5668-5673.
48. Suto M.J.et al. Novel approaches for the treatment of inflammatory diseases. inhibitors of NF-κB and AP-1 Curr. Pharm. Design. 3:1997;515-528.
49. Wong H.K.et al. Abnormal NF-κB activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J. Immunol. 163:1999;1682-1689.
50. Lee S.J.et al. A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-κB. Oncogene. 17:1998;1821-1826.